Analyzing Ginkgo Bioworks (NYSE:DNA) and Integrated Diagnostics (OTCMKTS:IDGXF)

Ginkgo Bioworks (NYSE:DNA) and Integrated Diagnostics (OTCMKTS:IDGXF) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Ginkgo Bioworks and Integrated Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2	1	0	0	1.33
Integrated Diagnostics	0	0	0	0	0.00

Ginkgo Bioworks currently has a consensus price target of $7.00, suggesting a potential downside of 3.98%. Given Ginkgo Bioworks’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Ginkgo Bioworks is more favorable than Integrated Diagnostics.

Valuation and Earnings

This table compares Ginkgo Bioworks and Integrated Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15 million	2.80	-$312.76 million	($5.01)	-1.46
Integrated Diagnostics	N/A	N/A	N/A	N/A	N/A

Integrated Diagnostics has lower revenue, but higher earnings than Ginkgo Bioworks.

Insider and Institutional Ownership

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ginkgo Bioworks and Integrated Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Integrated Diagnostics	N/A	N/A	N/A

Summary

Ginkgo Bioworks beats Integrated Diagnostics on 5 of the 8 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Integrated Diagnostics

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.